Tópico: [mp3 - en] Drogas, regulação, mercado e patentes

[Buckaroo Banzai]

Achei interessante. No site tem os highlights do debate em texto e podem ver se interessa ouvir

1:06:12 min, 15MB

http://www.econtalk.org/archives/2007/02/richard_epstein.html


Uns destaques que eu destaco:

[...]

How much incentive do we want to give pharmaceuticals to innovate? Is public itself selfish to demand 100% of rewards with nothing to pharmaceutical companies? Adam Smith. But patents do create problems in some industries. Software example: Microsoft, Apple: lots of small patents. Infringement of patent, shutting others down. How do you draft rules that work? Pharmaceuticals so far are closer to skyscrapers than to software code. Primogeniture. "Small broken things don't work well if all of them have to combine, but paradoxically, if you've got ten guys, each of whom has a viable factory, the last thing you want those guys to do is to fix prices, because at this point it becomes a monopoly."

[...]

What if the FDA didn't exist? Would that give drug companies incentives to dilute drugs? No. Underwriting labatories. Counterfeit drugs are less traceable when long supply chains are involved. How do you distinguish faked trademarks from contaminated or fake drugs? Who should enforce criminality questions? Generic drugs are not the same, have to shop. Which generics are close and which are weak or not so good? How do you find out? Do HMOs or doctors help sort that info out? Hot and new drugs catch attention. Blood pressure, diabetes: markets with high variation of success also have high demand. Philipson, Lakdawalla: Total drug sales go down when they become generic. Advertising correlated with brand names.